Published in Hepatology on June 26, 2011
Role of magnetic resonance elastography in compensated and decompensated liver disease. J Hepatol (2013) 1.20
Effect of obstructive sleep apnea on the sleep architecture in cirrhosis. J Clin Sleep Med (2013) 0.92
Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci (2014) 0.85
Nutrition and exercise in the management of liver cirrhosis. World J Gastroenterol (2014) 0.83
Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transpl Int (2013) 0.82
Changes in nutritional status after liver transplantation. World J Gastroenterol (2014) 0.81
Nutritional assessment in cirrhotic patients with hepatic encephalopathy. World J Hepatol (2015) 0.79
Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients. BMC Gastroenterol (2012) 0.79
Effects of an Exercise Programme on Functional Capacity, Body Composition and Risk of Falls in Patients with Cirrhosis: A Randomized Clinical Trial. PLoS One (2016) 0.75
Treating morbid obesity in cirrhosis: A quest of holy grail. World J Hepatol (2015) 0.75
To feed or what to feed in cirrhosis? Hepatology (2012) 0.75
Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle (2015) 0.75
Bariatric Surgery and Liver Transplantation. Gastroenterol Hepatol (N Y) (2017) 0.75
Adipokines in Liver Cirrhosis. Int J Mol Sci (2017) 0.75
Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis. Liver Int (2017) 0.75
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser (2000) 70.59
Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 41.22
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Review: a gentle introduction to imputation of missing values. J Clin Epidemiol (2006) 8.87
The epidemiology of obesity. Gastroenterology (2007) 8.35
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol (2005) 6.22
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology (1999) 5.75
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
Criteria for definition of overweight in transition: background and recommendations for the United States. Am J Clin Nutr (2000) 3.86
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
Surgery and portal hypertension. Major Probl Clin Surg (1964) 3.16
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology (2009) 2.33
Angiogenesis in liver disease. J Hepatol (2008) 2.31
Excess weight risk factor for alcoholic liver disease. Hepatology (1997) 2.22
Adipokines in liver diseases. Hepatology (2009) 2.14
Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology (2002) 2.02
Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ (2010) 2.01
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology (2005) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Risk factors of fibrosis in alcohol-induced liver disease. Hepatology (2002) 1.70
Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol (2002) 1.44
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol (2005) 6.22
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Vascular disorders of the liver. Hepatology (2009) 5.38
Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med (2010) 5.37
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology (2012) 3.86
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol (2006) 3.65
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med (2015) 3.47
Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology (2013) 3.31
Bacterial translocation (BT) in cirrhosis. Hepatology (2005) 3.07
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Multiple emergences of genetically diverse amphibian-infecting chytrids include a globalized hypervirulent recombinant lineage. Proc Natl Acad Sci U S A (2011) 2.78
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology (2008) 2.69
Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology (2013) 2.64
Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review. J Hepatol (2007) 2.52
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet (2011) 2.50
Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis (2008) 2.47
Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology (2012) 2.46
Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol (2010) 2.41
Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology (2006) 2.39
Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology (2010) 2.39
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol (2011) 2.37
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology (2009) 2.33
Significant small-bowel lesions detected by alternative diagnostic modalities after negative capsule endoscopy. Gastrointest Endosc (2008) 2.32
Comparison of the sequential organ failure assessment score with the King's College Hospital criteria and the model for end-stage liver disease score for the prognosis of acetaminophen-induced acute liver failure. Liver Transpl (2012) 2.32
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology (2010) 2.22
A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med (2011) 2.22
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
TIPS for refractory ascites: a single-centre experience. J Gastroenterol (2009) 2.19
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology (2002) 2.12
Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl (2014) 2.11
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07
Development of a modified sampling and calculation method for isotope plasma clearance assessment of the glomerular filtration rate in patients with cirrhosis and ascites. Nucl Med Commun (2013) 2.06
Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol (2013) 2.04
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology (2006) 2.03
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl (2007) 2.01
Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proc Natl Acad Sci U S A (2006) 1.97
Bleeding ectopic varices--treatment with transjugular intrahepatic porto-systemic shunt (TIPS) and embolisation. J Hepatol (2004) 1.92
Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol (2006) 1.90
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology (2014) 1.89
Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl (2007) 1.87
Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut (2011) 1.87
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol (2005) 1.87
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol (2007) 1.87
Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology (2006) 1.85
An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl (2007) 1.83
The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology (2006) 1.79
Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology (2009) 1.76
Recommendations for probiotic use--2008. J Clin Gastroenterol (2008) 1.76
A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl (2006) 1.73
Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology (2004) 1.71
How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers. Gastroenterology (2007) 1.70
Adrenal insufficiency in liver disease - what is the evidence? J Hepatol (2007) 1.69
Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl (2007) 1.68
Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut (2011) 1.66